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Background: This study aimed to examine the distribution of predefined phenotypes, 
demographic data, clinical outcomes, and treatment of patients who were included in the Polish 
cohort of the Phenotypes of COPD in Central and Eastern Europe (POPE) study.
Patients and methods: This was a sub-analysis of the data from the Polish cohort of the POPE 
study, an international, multicenter, observational cross-sectional survey of COPD patients in 
Central and Eastern European countries. The study included patients aged .40 years, with a 
confirmed diagnosis of COPD, and absence of exacerbation for at least 4 weeks before study 
inclusion. A total of seven Polish centers participated in the study.
Results:  Among the 430 Polish COPD patients enrolled in the study, 61.6% 
were non-exacerbators (NON-AE), 25.3% were frequent exacerbators with chronic bronchitis 
(AE CB), 7.9% were frequent exacerbators without chronic bronchitis (AE NON-CB), and 
5.1% met the definition of asthma-COPD overlap syndrome (ACOS). There were statistically 
significant differences among these phenotypes in terms of symptom load, lung function, 
comorbidities, and treatment. Patients with the AE CB phenotype were most symptomatic 
with worse lung function, and more frequently reported anxiety and depression. Patients with 
the ACOS phenotype were significantly younger and were diagnosed with COPD earlier than 
those with other COPD phenotypes; those with the ACOS phenotype were also more often 
atopic and obese.
Conclusion: There is significant heterogeneity among COPD patients in the Polish population 
in terms of phenotype and clinical outcome. The non-exacerbator phenotype is observed most 
frequently in Poland, while the frequent exacerbator with chronic bronchitis phenotype is the 
most symptomatic.
Keywords: chronic obstructive pulmonary disease, asthma-COPD overlap syndrome, 
phenotypes
Introduction
COPD is characterized by persistent respiratory symptoms and airflow limitation, as a 
result of airway and/or alveolar abnormalities usually caused by significant exposure 
to noxious particles or gases. The major risk factor for the development of COPD is 
tobacco smoking; other risk factors include age, previous history of asthma, respira-
tory infections, and genetic predisposition,1–6 as well as exposure to environmental 
pollution and smoke from biomass fuels.7,8
The idea that COPD is actually one disease instead of two (emphysema and chronic 
bronchitis) was first formed about 60 years ago. Although many COPD patients present 
features of both emphysema and chronic bronchitis, there are still patients with a 
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significant predominance of either one of these historical 
phenotypes. Moreover, there has been increased awareness 
of further heterogeneity among COPD (ie, more possible 
phenotypes), as reported in a series of new publications.9–11 
A COPD phenotype can be defined as “a single or combina-
tion of disease attributes that describe differences between 
individuals with COPD as they relate to clinically meaning-
ful outcomes”.10 In the most recent Spanish guidelines for 
COPD,11 the following COPD phenotype classifications were 
proposed: non-exacerbator, asthma-COPD overlap syndrome 
(ACOS), exacerbator with emphysema, and exacerbator with 
chronic bronchitis. However, there is currently no general 
consensus on the precise number of particular COPD phe-
notypes that can occur.
According to Miravitlles et al,12 the ability to identify a 
group of COPD subjects who will respond to specific treat-
ment is one of the most important features of “clinically 
relevant phenotypes”. Based on this concept, patients with 
the infrequent exacerbations phenotype may be treated with 
bronchodilators alone,13,14 while COPD patients with features 
of asthma (ACOS phenotype) benefit from additional treat-
ment with inhaled corticosteroids (ICS).15 Furthermore, 
roflumilast (a selective inhibitor of phosphodiesterase type 4) 
has been shown to reduce the number of exacerbations only 
in COPD patients with chronic bronchitis and frequent 
exacerbations.16 Therefore, understanding of these pheno-
types is critical for guiding COPD treatment.
Numerous studies around the world have attempted to 
identify and estimate the prevalence of COPD phenotypes in 
various populations, each with slightly differing outcomes.17,18 
These differences in study outcomes can probably be attrib-
uted to the diversity of environmental pollution, smoking 
prevalence, socioeconomic status, and general health of 
populations living in particular countries (including European 
populations) and world regions. Therefore, the objectives 
of the Phenotypes of COPD in Central and Eastern Europe 
(POPE) study were to investigate the distribution of different 
COPD phenotypes, patient characteristics, and treatment 
patterns of COPD patients in Central and Eastern Europe 
(CEE) countries.19
The current paper focuses on the distribution of pheno-
types, demographic data, clinical outcomes, and treatment 
of patients who were included in the Polish cohort of the 
POPE study.
Patients and methods
Study design
The POPE study was an international, multicenter, observa-
tional, cross-sectional survey of COPD patients in CEE countries 
(ClinicalTrials.gov registry identifier: NCT02119494). 
Poland was among 11 countries participating in the study, 
with seven centers enrolling subjects. The study was 
performed in accordance with the ethics principles of the 
Declaration of Helsinki. The Ethics Committee of the Polish 
coordinating center (University of Silesia in Katowice) 
reviewed the study protocol and decided that the study 
did not need ethical approval due to its non-interventional 
design. All enrolled patients gave written informed consent 
to participate in the study.
A complete list of Polish centers participating in the 
study is given in Table 1. Details of the methodology 
and recruitment strategy used in the study are described 
elsewhere.19 Briefly, COPD patients were examined in an 
outpatient setting and had to fulfill the following inclusion 
criteria: aged more than 40 years, confirmed diagnosis of 
COPD with post-bronchodilator forced expiratory volume 
in 1 second (FEV
1
)/forced vital capacity (FVC) ,0.7, and 
absence of exacerbation for at least 4 weeks before study 
inclusion. Only COPD patients with smoking history equal 
to or more than 10 pack-years were included. Although the 
inclusion criteria for the POPE cohort involved patients with 
a smoking history of less than 10 pack-years and pronounced 
additional exposure to other COPD risk factors, no such indi-
viduals were enrolled in the Polish sub-cohort. An electronic 
case report form was used for data collection. Patients were 
enrolled between April 2014 and July 2015. Distribution of 
predefined phenotypes, as well as the association between 
phenotype and clinical outcomes, was evaluated.
study cohort characteristics
The following data were collected for each patient: allergy 
and atopy status, COPD symptoms (dyspnea at rest/during 
exercise, fatigue, cough, chronic sputum production, purulent 
Table 1 Polish centers participating in the POPE study
Number Centre name
1 Department of Lung Diseases and Respiratory Failure, 
Regional Center of Pulmonology, Bydgoszcz
2 Department of Internal Medicine, Pulmonary Diseases 
and Allergy, Medical University of Warsaw, Warsaw
3 Department of Allergology and Pneumonology, Medical 
University of Gdańsk, Gdańsk
4 Department of Lung Diseases, Regional Hospital Center, 
Jelenia Góra
5 Department of Pulmonology, Allergology and Respiratory 
Oncology, Poznań University of Medical Sciences, Poznań
6 Department of Pulmonology, Jagiellonian University 
Medical College, Kraków
7 Department of Pneumology, School of Medicine in 
Katowice, Medical University of Silesia, Katowice
Abbreviation: POPe, Phenotypes of COPD in Central and eastern europe.
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expectoration), smoking status and other respiratory risk 
factors, acute respiratory events (including number of COPD 
exacerbations), concomitant respiratory and non-respiratory 
diseases, pharmacological and non-pharmacological treat-
ment. Patients were classified into one of four GOLD 2014 
categories (A–D) based on the value of the post-bronchodilator 
FEV
1
, history of COPD exacerbations, and intensity of 
respiratory symptoms using the modified Medical Research 
Council (mMRC) dyspnea scale and the COPD Assessment 
Test (CAT).1,2,20,21
Phenotype definitions
Patients were divided according to predefined phenotypes. 
The following algorithm was used to distinguish specific 
phenotypes among recruited COPD patients: 1) patients 
with asthma diagnosis before the age of 40 years or a posi-
tive bronchodilator test in the previous 12 months with a 
history of atopy and/or allergy were considered a mixed 
COPD-asthma phenotype (ACOS), 2) patients with less 
than two exacerbations in the previous year were classified 
as the non-exacerbator phenotype (NON-AE), 3) frequent 
exacerbators reporting chronic cough and expectoration for 
more than 3 months per year over 2 consecutive years were 
described as frequent exacerbators with chronic bronchitis 
(AE CB), 4) the remaining frequent exacerbators were clas-
sified as frequent exacerbators without chronic bronchitis, 
predominantly with emphysema (AE NON-CB).19
statistical analysis
Categorical data were summarized as absolute and relative 
values, while continuous data were presented as median and 
5th–95th percentile. Differences among the groups were 
analyzed using Kruskal–Wallis test and the Mann–Whitney 
U-test for pairwise comparisons; Fisher exact test was used 
to assess differences in categorical data. All tests were 
two-tailed; a p-value of ,0.05 was considered significant. 
Statistical analyses were performed using SPSS version 
22.0.0 (IBM Corporation, Armonk, NY, USA, 2013).
Results
Distribution of phenotypes
A total of 430 patients with COPD were enrolled in the 
study; all patients were included in the final analysis. The 
majority of patients (61.6%) were classified as the NON-AE 
phenotype. The AE CB and AE NON-CB phenotypes were 
observed in 25.3% and 7.9% of the study cohort, respec-
tively, and 5.1% of patients met the definition for the ACOS 
phenotype (Figure 1).
Characteristics of patients according to 
phenotypes
Detailed characteristics of patients with the different COPD 
phenotypes are summarized in Table 2. The percentage of 
males was higher in the NON-AE phenotype compared to 
the AE NON-CB and AE CB phenotypes. Patients with 
the ACOS phenotype were significantly younger and their 
diagnosis of COPD was established earlier than in the other 
phenotypes; they were also more often atopic and obese than 
those with the other COPD phenotypes.
Significant differences between the phenotypes were 
observed in terms of symptoms, CAT and mMRC scores, and 
airflow limitation (measured as FEV
1
 % of predicted). Those 
with the AE CB phenotype had the most intense symptoms 
(the highest CAT scores), the poorest tolerance of physical 
effort, and the most impaired lung function (the lowest 
FEV
1
 % of predicted). In line with these severe symptoms 
of lung disease, depression and anxiety were most common 
among AE CB subjects.
The global weight of comorbidities, measured by the 
Charlson index, was similar among all the groups (Table 3); 
however, atopy was significantly more common in those with 
the ACOS phenotype. We also found smoking habits were 
different among the phenotypes: there were fewer current 
smokers in the AE CB group compared to the ACOS and 
NON-AE groups. In addition, those with the AE CB phe-
notype smoked more cigarettes (measured by pack-years) 
compared to patients with the ACOS phenotype.
Figure 1 (A) Distribution of phenotypes and (B) GOLD categories (A–D) in the Polish study cohort.
Abbreviations: ACOS, asthma-COPD overlap syndrome; NON-AE, non-exacerbator; AE NON-CB, exacerbator without chronic bronchitis; AE CB, frequent exacerbator 
with chronic bronchitis.
AE CB; 25.3%
A B
ACOS; 5.1%
AE NON-CB; 7.9% GOLD D; 58.6%
GOLD C; 2.6%
GOLD B; 30.9%
GOLD A; 7.9%
NON-AE; 61.6%
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Table 2 Baseline characteristics of patients with different COPD phenotypes
Phenotype
ACOS (a)
N=22
NON-AE (b)
N=265
AE NON-CB (c)
N=34
AE CB# (d)
N=109
p-value
number of men (%) 13 (59.1%) 194 (73.2%)c,d 19 (55.9%)b 68 (62.4%)b 0.041
Age at inclusion (years) 59.0 (44.0; 70.0)b–d 67.0 (54.0; 83.0)a 68.0 (50.0; 88.0)a 68.0 (56.0; 83.0)a ,0.001
Age at COPD diagnosis (years) 49.5 (40.0; 60.0)b–d 61.0 (45.0; 75.0)a 60.0 (41.0; 75.0)a 57.0 (42.0; 73.0)a ,0.001
area
Urban 19 (90.5%) 188 (72.0%) 30 (88.2%) 80 (79.2%) 0.049
rural 2 (9.5%) 73 (28.0%) 4 (11.8%) 21 (20.8%)
Dyspnea
exertional 20 (90.9%) 240 (90.6%)d 32 (94.1%) 109 (100.0%)b 0.001
Resting 4 (18.2%) 23 (8.7%) 3 (8.8%) 16 (14.7%) 0.191
Cough 18 (81.8%)c 190 (71.7%)c,d 14 (41.2%)a,b,d 104 (95.4%)b,c ,0.001
sputum 14 (63.6%) 159 (60.0%) 0 (0%) 109 (100%) 0.823*
Fatigue 10 (45.5%) 96 (36.5%) 16 (47.1%) 43 (39.4%) 0.560
Smoking
ex-smokers 13 (59.1%)d 188 (70.9%)d 28 (82.4%) 90 (82.6%)a,b 0.025
Current smokers 9 (40.9%)d 77 (29.1%)d 6 (17.6%) 19 (17.4%)a,b
Smoking burden (pack-years) 22.5 (14; 36)d 38 (25; 50) 35 (24; 49) 43 (30; 56)a 0.082
BMI (kg/m2) 29.1 (22.6; 41.2)b,d 27.1 (19.8; 36.9)a,c 28.8 (20.6; 43.0)b 27.2 (18.3; 42.2)a 0.023
FeV1 (% predicted) 59.3 (34.5; 81.4)
d 55.7 (26.8; 92.1)d 52.4 (28.8; 74.0) 42.6 (19.5; 77.2)a,b ,0.001
FVC (% predicted) 83.9 (55.1; 110.8) 87.2 (52.8; 123.4) 76.8 (49.4; 126.5) 79.3 (48.5; 116.1) 0.166
CaT – total score 16.0 (6.0; 33.0)d 18.0 (5.0; 32.0)d 19.5 (6.0; 32.0) 24.0 (8.0; 35.0)a,b ,0.001
mMrC
0 4 (18.2%)d 23 (8.7%)d 2 (5.9%)d 0 (0.0%)a–c ,0.001
1 4 (18.2%)d 77 (29.1%)d 3 (8.8%)d 7 (6.4%)a–c
2 11 (50.0%)d 86 (32.5%)d 14 (41.2%)d 33 (30.3%)a–c
3 2 (9.1%)d 56 (21.1%)d 14 (41.2%)d 39 (35.8%)a–c
4 1 (4.5%)d 23 (8.7%)d 1 (2.9%)d 30 (27.5%)a–c
GOLD categories
a 2 (9.1%)d 32 (12.1%)c,d 0 (0.0%)b 0 (0.0%)a,b ,0.001
B 8 (36.4%)c,d 125 (47.2%)c,d 0 (0.0%)a,b 0 (0.0%)a,b
C 2 (9.1%) 4 (1.5%)c 3 (8.8%)b 2 (1.8%)
D 10 (45.4%)c,d 104 (39.2%)c,d 31 (91.2%)a,b 107 (98.2%)a,b
Other risk factors
Yes (%) 6 (27.3%) 52 (19.6%) 2 (5.9%) 24 (22%) 0.15
Workplace environment 5 (22.7%) 48 (18.1%) 1 (2.9%) 17 (15.6%) 0.12
Frequent exposure to outdoor 
pollution (eg, organic dusts)
0 2 (0.76%) 0 0 0.31
exposure to indoor pollution 1 (4.6%) 4 (1.5%) 1 (2.9%) 4 (3.7%) 0.54
Cooking fire without ventilation 1 (4.6%) 4 (1.5%) 0 5 (4.6%) 0.34
Total number of exacerbations 
(in the last 12 months)
1 (0–2)b–d 0 (0–1)a,c,d 2 (2–3)a,b 3 (2–4)a,b ,0.001
Notes: Categorical parameters are described by absolute (relative) frequencies, and statistical significance was determined by the Fisher exact test. Indices a–d indicate 
a statistical significant difference between two phenotypes (Fisher exact test). Continuous parameters are described by median (5th; 95th percentiles) and valid N, and 
statistical significance was determined by the Kruskal–Wallis test. Indices a–d indicate a statistical significant difference between two phenotypes (pairwise comparisons). 
*Statistical significance is tested only for ACOS and NON-AE. #According to the classic definition of chronic bronchitis, patients were diagnosed as having this condition if 
cough occurred every day with sputum production and lasted for $3 months for 2 consecutive years. no patients with ae nOn-CB have sputum and all patients with ae 
CB have sputum. Bold represent statistically significant values (p,0.05).
Abbreviations: ACOS, asthma-COPD overlap syndrome; NON-AE, non-exacerbator phenotype; AE NON-CB, frequent exacerbators without chronic bronchitis, 
predominantly with emphysema; AE CB, frequent exacerbators with chronic bronchitis; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; CAT, COPD Assessment Test; mMRC, modified Medical Research Council.
There were also differences between treatment regimens 
among patients with various COPD phenotypes (Table 4). 
Triple therapy, including long-acting muscarinic antagonists 
(LAMA), long-acting beta agonists (LABA), and ICS, was 
most commonly used in patients with the AE CB phenotype. 
Almost twice as many patients with the AE CB phenotype 
were treated with the LAMA+LABA+ICS combination 
compared to those with the NON-AE phenotype (p,0.001). 
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Similarly, treatment with bronchodilators only (one or both) 
was more frequent in those with the NON-AE phenotype 
compared to the AE CB phenotype (Table 4).
Discussion
To the best of our knowledge, this is the first paper present-
ing the characteristics and relative prevalence of different 
COPD phenotypes in Poland. In this paper, we reported 
the distribution, clinical characteristics, and treatment of 
predefined COPD phenotypes in the Polish cohort of patients 
recruited in the POPE study. Several reasons stood behind the 
decision to analyze the Polish sub-cohort of the POPE study. 
Among countries participating in the POPE study, Poland’s 
geographical location is the least favorable, with hard coal 
remaining the main source of energy. This could affect the 
epidemiology of COPD phenotypes. The distribution of 
COPD phenotypes varies among countries taking part in the 
POPE project,22 which also provoked the authors to take a 
deeper look at the situation in Poland.
It should be highlighted that patients were assigned to the 
four different COPD phenotypes according to a predefined 
algorithm.19 We found that patients with the frequent exac-
erbator phenotype constituted one-third of all COPD patients 
participating in the study. The vast majority of frequent 
Table 3 Comorbidities in patients with different COPD phenotypes
Phenotype
ACOS (a)
N=22
NON-AE (b)
N=265
AE NON-CB (c)
N=34
AE CB (d)
N=109
p-value
Depression 0 (0.0%)c,d 16 (6.0%)c 9 (26.5%)a,b 17 (15.6%)a,b ,0.001
anxiety 1 (4.6%) 11 (4.2%)d 3 (8.8%) 13 (11.9%)b 0.044
Insomnia 2 (9.1%) 33 (12.5%) 3 (8.8%) 31 (28.4%) 0.77
sleep apnea 2 (9.1%)
n=22
32 (12.4%)
n=259
2 (6.1%)
n=33
12 (11.1%)
n=108
0.73
Bronchiectasis 4 (3.5%)
n=21
19 (7.4%)
n=257
3 (9.1%)
n=33
12 (11.0%)
n=109
0.27
Charlson 
comorbidity index
1 (1; 4) 2 (1; 4) 2 (1; 6) 2 (1; 5) 0.15
atopy 16 (72.7%)b–d 14 (5.3%)a 1 (2.9%)a 3 (2.8%)a ,0.001
Notes: Categorical parameters are described by absolute (relative) frequencies, and statistical significance was determined by the Fisher exact test. Indices a–d indicate a 
statistical significant difference between two phenotypes (Fisher exact test). Continuous parameters are described by median (5th; 95th percentiles) and valid N, and statistical 
significance was determined by the Kruskal–Wallis test. Indices a–d indicate a statistical significant difference between two phenotypes (pairwise comparisons). Bold represent 
statistically significant values (p,0.05).
Abbreviations: ACOS, asthma-COPD overlap syndrome; NON-AE, non-exacerbator phenotype; AE NON-CB, frequent exacerbators without chronic bronchitis, 
predominantly with emphysema; AE CB, frequent exacerbators with chronic bronchitis.
Table 4 Medications used to treat patients with different COPD phenotypes
Phenotype
ACOS (a) NON-AE (b) AE NON-CB (c) AE CB (d) p-value
laMa (monotherapy) 0 (0.0%) 22 (8.3%)d 3 (8.8%) 1 (0.9%)b 0.013
laBa (monotherapy) 0 (0.0%) 48 (18.1%)d 2 (5.9%) 3 (2.8%)b ,0.001
ICs (monotherapy) 0 (0.0%) 2 (0.8%) 0 (0.0%) 0 (0.0%) 0.999
laMa+laBa 2 (9.1%) 54 (20.4%)d 8 (23.5%) 9 (8.3%)b 0.013
laMa+ICs 0 (0.0%) 1 (0.4%) 0 (0.0%) 2 (1.8%) 0.477
laBa+ICs 6 (27.3%) 30 (11.3%) 2 (5.9%) 19 (17.4%) 0.053
laMa+laBa+ICs 14 (63.6%) 96 (36.2%)d 19 (55.9%) 74 (67.9%)b ,0.001
LAMA (all regimens) 16 (72.7%) 173 (65.3%)c,d 30 (88.2%)b 86 (78.9%)b 0.006
LABA (all regimens) 22 (100%) 228 (86%) 31 (91.2%) 105 (96.3%) 0.15
ICS (all regimens) 20 (90.9%)b,c 129 (48.7%)a,d 21 (61.8%)a,d 95 (87.2%)b,c ,0.001
Mucoactive drugs 0 (0.0%) 7 (2.6%)d 0 (0.0%) 12 (11.0%)b 0.359
Roflumilast 0 (0.0%) 2 (0.8%) 1 (2.9%) 0 (0.0%) 0.384
Antibiotics (long-term or pulsed) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%) 0.359
Notes: Categorical parameters are described by absolute (relative) frequencies, and statistical significance was determined by the Fisher exact test. Indices a–d indicate a 
statistical significant difference between two phenotypes (Fisher exact test). Bold represent statistically significant values (p,0.05).
Abbreviations: ACOS, asthma-COPD overlap syndrome; NON-AE, non-exacerbator phenotype; AE NON-CB, frequent exacerbators without chronic bronchitis, 
predominantly with emphysema; AE CB, frequent exacerbators with chronic bronchitis; LAMA, long-acting muscarinic antagonists; LABA, long-acting beta agonists; 
ICs, inhaled corticosteroids.
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exacerbators were patients with clinical features correspond-
ing to chronic bronchitis (75%). The percentage of patients 
with the ACOS phenotype was relatively low (5.1%). Our 
study also demonstrated that patients with different COPD 
phenotypes present different disease characteristics in terms 
of magnitude of symptoms (measured by CAT and mMRC 
scores), severity of airflow limitation, smoking habit, atopy 
status, and some comorbidities. Compared to other pheno-
types, patients with the AE phenotypes were more symp-
tomatic and had the greatest degree of airway obstruction 
(based on FEV
1
 % of predicted).
Some previous studies have also evaluated the distribu-
tion of various COPD phenotypes. Cosio et al found the 
following distribution of COPD phenotypes when using the 
definitions found in the Spanish guidelines: non-exacerbator 
with either chronic bronchitis or emphysema, 66.2%; ACOS, 
15.0%; frequent exacerbator with chronic bronchitis, 11.9%; 
and frequent exacerbator with emphysema, 4.6%.17 Using a 
similar definition of phenotypes, Miravitilles et al observed 
the following frequencies of phenotypes: non-exacerbator, 
60.6%; ACOS, 15.9%; exacerbator with chronic bronchitis, 
19.3%; and exacerbator without chronic bronchitis, 4.3%.18 
The definitions of COPD phenotypes used in the POPE 
study were similar to, but not exactly the same as, those 
used in the Spanish guidelines. As such, the distributions of 
COPD phenotypes in the Polish cohort of POPE study were 
slightly different to those observed in the studies by Cosio 
et al and Miravitilles et al. In particular, we found a lower 
proportion of patients with ACOS in the Polish population 
(5.1% vs 15% and 15.9% in the studies by Cosio et al and 
Miravitilles et al, respectively) and a higher percentage of 
frequent exacerbators with chronic bronchitis (25.3% vs 
11.9% and 19.3%, respectively). This observation is consis-
tent with the results of the study published by Calle Rubio, 
which revealed an ACOS prevalence of 6.5%.23 Another 
study, using modified 2012 Spanish COPD guidelines to 
define ACOS, found a prevalence of 5% for the patients with 
COPD caused by tobacco,24 which is similar to the results 
described in our study.
However, the percentage of patients with ACOS found in 
our study was significantly lower than the pooled prevalence 
of ACOS calculated in the meta-analysis by Alshabanat et al.25 
This may be due to the different criteria used for the diagnosis 
of ACOS among studies, including the POPE study. Indeed, 
the exact definition of asthma and COPD overlap remains 
ambiguous. Even the most recent document developed by 
the science committee of the Global Initiative for Asthma 
does not give a definition for ACOS, but instead describes it 
as a syndrome characterized by persistent airflow limitation 
with several features usually associated with asthma and 
several features usually associated with COPD.26 Indeed, it 
has previously been shown how the diagnostic criteria used 
for ACOS can influence epidemiology.27 Meanwhile, in the 
entire POPE study (in which the diagnostic criteria of ACOS 
was kept uniform), the distribution of the ACOS phenotype 
across the different countries had the lowest heterogeneity.22 
Therefore, more studies using the same diagnostic criteria 
for ACOS are required to compare the prevalence of ACOS 
in different countries.
The varying magnitude of environmental pollution, 
smoking habits, and comorbidities across European popu-
lations may also contribute to the observed differences 
in phenotype distribution. The levels of air pollution are 
higher in CEE countries than in Western Europe. Poland 
is unfortunately one of the leaders in poor air quality, 
and widely exceeds the daily limit for particular matter.28 
Exposure to ambient air pollution, especially to particulate 
matter, is a major risk factor for pulmonary diseases such 
as asthma, chronic bronchitis, or pneumonia.29 In the entire 
POPE study, 63% of the COPD patients were NON-AE, 
20.4% were AE CB, 9.5% were AE-NON CB, and 6.9% 
were ACOS.22 The frequencies of particular phenotypes in 
the Polish cohort were more similar to those observed for 
all CEE countries participating in the POPE study, which 
emphasizes the importance of precise phenotype definitions. 
Furthermore, similar environmental conditions are likely to 
give congruous observation results. Therefore, taking these 
factors into account, our percentage of patients with ACOS 
is not surprisingly low.
Previous studies have shown that the ACOS and CB 
phenotypes are characterized by the most severe clinical 
course. In the PLATINO study, asthma and overlap patients 
were characterized by higher risk of exacerbations and 
worse general health status.30 Similarly, COPD patients with 
chronic bronchitis had worse lung function and general health 
status, and had more respiratory symptoms, physical activity 
limitation, and exacerbations than those with other COPD 
phenotypes.31 In our study, both ACOS and AE CB patients 
received the highest medication regimens (more than 60% of 
subjects on triple therapy), suggesting a more severe disease. 
However, in terms of symptom load, those with the AE CB 
phenotype had the worse scores.
Our observations are similar to the results from the French 
study by Caillaud et al (ie, the “INITIATIVES Broncho-
Pneumopathie Chronique Obstructive” cohort).32 This study 
showed that patients with ACOS suffer more from atopic 
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diseases and obesity and use more medication, while disease 
severity (symptoms, exacerbations, comorbidities) and prog-
nosis (mortality) do not differ from “pure” COPD patients.32 
Meanwhile, the characteristics of frequent exacerbators with 
chronic bronchitis are more consistent. Like in our study, 
Cosio et al found that frequent exacerbators with chronic 
bronchitis reported more severe symptoms and were treated 
with more medications than patients with other COPD phe-
notypes.17 Similar observations were made in the COPDGene 
study: chronic bronchitis was associated with more severe 
respiratory symptoms and higher risk of exacerbations.33
The Polish guidelines for COPD management are strongly 
based on GOLD strategy and therefore do not indicate a 
phenotype-based strategy.34 We found differences in the 
administered medication among phenotypes, which likely 
reflects some overlap between a phenotype-based treat-
ment approach and treatment based on GOLD classification 
(as currently recommended). For example, the ACOS and 
frequent exacerbator phenotypes were expected to have the 
highest proportions of patients treated with ICS. ICS were 
recommended by GOLD 2014 for patients with high risk of 
exacerbations (assessed based on lung function and prior 
history of exacerbations).1 It is known that ACOS patients 
with features of asthmatic inflammation in the airways 
especially benefit from ICS therapy.15 Nonetheless, not all 
ACOS and frequent exacerbators received ICS in our study, 
which to some extent can be explained by the fact that some 
of the GOLD C and D subjects among frequent exacerba-
tors had FEV
1
 values .50% of predicted. This suggests that 
physicians may pay too little attention to the asthma and 
COPD overlap, and the GOLD strategy document should 
provide more precise diagnostic criteria. Meanwhile, many 
of the GOLD C and D subjects did receive ICS, although not 
all of them experienced frequent exacerbations. The reason 
that the majority of non-frequent exacerbator patients were 
treated with ICS could be low FEV
1
 values, which places 
them into the GOLD C and D categories.1
The abovementioned observations, together with the high 
use of triple therapy in NON-AE patients (despite current 
recommendations), suggest that a better strategy for treating 
patients with COPD is warranted. Therefore, considering a 
phenotype-based therapeutic strategy for COPD may be more 
appropriate. Indeed, the new GOLD 2017 strategy docu-
ment redefines the GOLD A–D categories,2 excluding low 
FEV
1
 value as a predictor of future exacerbations, thereby 
making information on symptoms and past exacerbations 
more crucial. It is possible the percentage of subjects in the 
GOLD A–D categories will change if FEV
1
 values are not 
considered. The updated guidelines also diminish the role 
of ICS therapy in COPD; therefore, the overuse of ICS-
containing treatment in non-exacerbating COPD patients is 
an important practical observation. It would be interesting to 
determine whether data from the Polish POPE study cohort, 
which adhered to the new GOLD strategy document, are 
comparable to the entire POPE cohort data.35
Our study does have some limitations. First, the number 
of recruited patients was relatively small compared to other 
population-based epidemiological studies. Second, patients 
were classified to predefined phenotypes according to 
a simple algorithm taking into account only symptoms, 
history of exacerbations, and previous diagnosis of asthma.19 
We realize that the use of more advanced diagnostic methods 
(such as induced sputum analysis or computed tomography 
scanning) would enable more extensive and more precise 
phenotyping, which may further affect the choice of the 
most effective therapeutic options. On the other hand, the 
limited number of phenotypes that were diagnosed based 
on easily available clinical data may be considered a study 
advantage, as this approach better fits with real-life clinical 
practice. Third, it was the interview with the patient and the 
analysis of available medical documentation that served as 
the main source of information about any comorbid con-
ditions. Performing additional diagnostics tests or using 
questionnaires to recognize depressive or anxiety disorders 
would certainly improve the accuracy of the analysis. Finally, 
as six of the seven centers recruiting the patients were 
teaching hospital-based pulmonary departments located in 
large Polish cities, we cannot exclude some bias in patient 
selection. These include place of patient residence (74% of 
enrolled patients were residents of urban areas) and selection 
of patients with more severe disease. Indeed, the proportion 
of patients with severe disease in outpatient departments of 
tertiary referral university hospitals is likely higher than in 
other medical centers. We eagerly await the distribution and 
characteristics of COPD phenotypes found in sub-cohorts of 
patients evaluated in other countries.
Conclusion
This study provides information regarding distribution, 
clinical presentation, and treatment modalities of predefined 
COPD phenotypes observed in the Polish population. Further 
research is needed to evaluate the natural course of COPD 
phenotypes and whether a phenotype-based approach for the 
treatment of COPD is associated with better clinical outcomes 
than current approaches relying on lung function, history of 
exacerbations, and symptoms.
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